Hosted on MSN

Vor Biopharma approves stock option repricing plan

Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence. Subscribe to TipRanks' Smart Investor Picks and see our data in action through our ...
Yahoo Finance

Vor Biopharma (VOR): Valuation Check After Positive Telitacicept Phase 3 Data and Upbeat JPMorgan Coverage

Vor Biopharma (VOR) has jumped onto investors’ radar after strong Phase 3 data for telitacicept in IgA nephropathy, paired with upbeat new Wall Street coverage that frames the drug’s long term ...
Seeking Alpha

Vor Bio spikes as J.P. Morgan starts at Overweight on lead asset

Vor Biopharma (VOR) rose ~17% on Tuesday after J.P. Morgan initiated its coverage with an Overweight recommendation and a Dec. 2026 price target of $43, citing a potential blockbuster status for the ...
Investing

JPMorgan initiates Vor Biopharma stock with Overweight rating, $43 target

Investing.com - JPMorgan has initiated coverage on Vor Biopharma, Inc. (NASDAQ:VOR) with an Overweight rating and a price target of $43.00, highlighting the potential of the company’s telitacicept ...
Yahoo Finance

Vor Biopharma (VOR) Is Up 45.6% After Telitacicept Phase 3 Win And JPMorgan Nod Has The Bull Case Changed?

In recent months, Vor Biopharma closed a US$424.83 million shelf registration, repriced employee stock options, and reported positive late-stage clinical data for its autoimmune drug candidate ...
Investing

JPMorgan initiates Vor Biopharma stock with Overweight rating on telitacicept potential

Investing.com - JPMorgan initiated coverage on Vor Biopharma, Inc. (NASDAQ:VOR) with an Overweight rating and a $43.00 price target, citing the potential of its telitacicept drug. The target ...
pharmaphorum

Vor Bio winding down as multiple biotechs downsize

The challenges facing biotechs amid the ongoing financial fallout have resulted in the winding down of one US biotech, Vor Bio, and job losses at a clutch of other firms. Cambridge, ...
Seeking Alpha

Vor Biopharma: J.P. Morgan Makes Bull Case After Corporate Actions Slam Stock Price

Vor Biopharma Inc. offers a high-risk, high-reward play on U.S. commercialization of telitacicept, a dual-target autoimmune drug approved in China. Complex warrant issuances and reverse stock split ...
Morningstar

Vor Biopharma Inc Ordinary Shares VOR

Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings.
IEEE

IEEE Communications Surveys and Tutorials

Abstract: I welcome you to the fourth issue of the IEEE Communications Surveys and Tutorials in 2021. This issue includes 23 papers covering different aspects of communication networks. In particular, ...
Morningstar

Vor Biopharma Inc Ordinary Shares

Get access to full transcripts of current and past earnings calls to further evaluate Vor Biopharma Inc Ordinary Shares (VOR:XNAS) stock's performance and strategic direction ...